EGFR and adenocarcinoma: To explore the relationship between gene mutations and TAM distribution, we analyzed both EGFR and TP53 mutation statuses in 117 adenocarcinomas and quantified M1 and M2 TAMs through immunohistochemistry (IHC) staining (Supplementary Fig. 1C).